ing taken by 25.7% of patients with an indication; 47.3% of patients with MI or coronary revascularization were taking a statin compared with 40.4%, 33.8% and 18.9% with LDL-C ≥190 mg/dL and 10-year CVD risk >7.5%, respectively (Table 1). In multivariable analysis and compared with patients with history of MI or coronary revascularization, those with diabetes, LDL-C ≥190 mg/dL, and 10-year CVD risk >7.5% were less likely to be taking a statin (prevalence ratio [95% confidence interval] 0.68 [0.58–0.79], 0.71 [0.50–1.01], and 0.39 [0.34–0.46], respectively). Among patients who had ever taken a statin, 27.7% had discontinued treatment before 2013: 23.6% with history of MI or coronary revascularization, 27.7% with diabetes, 30.9% with LDL-C ≥190 mg/dL and 27.9% of those with 10-year CVD risk >7.5%.

Conclusions: A majority of HIV-infected patients with an indication for a statin who were taking this medication, partially resulting from a high rate of treatment discontinuation.

Acknowledgement/Funding: Amgen; NIH/NHLBI (K23 HL126570)

P169 | BEDSIDE
Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes
K.C. Koskinas1, B. Gencer2, L. Raaber1, A. Karagiannis1, D. Nanchen3, D. Carballo4, S. Carballo2, R. Klingenberg4, D. Hege3, C. Matter4, T.F. Luscher2, N. Rodondi6, S. Windeker3, F. Mach1, 1Bern University Hospital, Cardiology, Bern, Switzerland; 2Geneva University Hospitals, Cardiology, Geneva, Switzerland; 3University of Lausanne, Department of Cardiology and Community Medicine, Lausanne, Switzerland; 4University Heart Center, Department of Cardiology, University of Zurich, Switzerland; 5Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 6University Hospital of Bern, Department of General Internal Medicine, Bern, Switzerland

Background: PCSK9 inhibitors have emerged as a promising treatment option for management of dyslipidemia. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and the American College of Cardiology (ACC) have issued recommendations regarding the use of PCSK9 inhibitors in selected patients. Treatment eligibility rates according to these recommendations in real-world clinical practice remain unknown.

Purpose: To assess in a contemporary, real-world setting the eligibility for PCSK9 inhibitors after acute coronary syndromes (ACS) according to ESC/EAS vs. ACC recommendations.

Methods: We analysed a prospective Swiss cohort of 2,023 patients hospitalized for ACS between 2009 and 2014. Patients received optional secondary prevention treatment. One year after enrollment, eligibility for PCSK9 inhibitor treatment was defined according to the ESC/EAS vs. ACC criteria on the basis of on-treatment levels of low-density lipoprotein cholesterol (LDL-C); achieved reduction in LDL-C; and high-risk clinical characteristics (rapid disease progression or comorbidities). Familial hypercholesterolemia (FH) was defined using the Dutch Lipid Clinic Network criteria. Because treatment with ezetimibe on top of maximally tolerated statin is included in both the ESC/EAS and ACC eligibility algorithms, we modelled a fixed relative reduction of 24% in LDL-C levels at one year in all patients not treated with ezetimibe.

Results: At one year, 94.3% of patients were treated with statin (55.3% with high-intensity statin) and 5.8% with ezetimibe. Mean LDL-C levels were 2.19±0.86 mmol/l at one year, and 35.8% of patients had LDL-C levels ≥190 mg/dL at one year. Eligibility for PCSK9 inhibitor treatment was 47.3% (95% CI: 0.56–0.72) for ESC/EAS criteria and 3.99 (95% CI: 0.34–0.66) for ACC criteria. Among patients who were eligible for PCSK9 inhibitor treatment at one year was 2.7% according to ESC/EAS criteria vs. 13.4% based on ACC criteria. No difference between ESC/EAS and ACC criteria was observed in the achievement of LDL-C reduction targets.

Conclusion: We observed a U-shaped association between adipose tissue content of ALA and the risk of ischemic stroke. After appropriate exclusions, we included 1735 cases for analysis. Multivariate analyses that were conducted using restricted cubic splines and adjustment for established ischemic stroke risk factors showed a U-shaped association between adipose tissue content of ALA and the risk of ischemic stroke, but this association was not statistically significant (Figure). In analyses of adipose tissue content of ALA expressed in quintiles, the hazard ratios in the second (0.95; 95% CI: 0.78, 1.16), third (0.86; 95% CI: 0.70, 1.08), fourth (0.93 95% CI: 0.76, 1.14) and fifth quintile (1.01 95% CI: 0.82, 1.23) also revealed a U-shaped association, but the hazard ratios were not statistically significant.

Results: A total of 57,053 participants aged 50–64 years of age were enrolled between 1993–97 into the Danish Diet, Cancer and Health Cohort. Potential participants were selected on the basis of BMI, waist circumference, and a random stratified sampling of the total cohort (n=3500). Statistical analyses were performed using standard statistical software, and hazard ratios with 95% confidence intervals were computed.

Conclusion: We observed a U-shaped association between adipose tissue content of ALA and the risk of ischemic stroke, but the association was not statistically significant.

P170 | BEDSIDE
Adipose tissue content of alpha-linolenic acid and the risk of ischemic stroke - A Danish case-cohort study
C.S. Bork1, S.K. Veno1, M.U. Jakobsen2, S. Lundbye-Christensen3, E.B. Schmidt1, K. Overdav2, 1Aalborg University Hospital, Department of Cardiology, Aalborg, Denmark; 2Aarhus University, Department of Public Health, Section for Epidemiology, Aarhus, Denmark; 3Aalborg University Hospital, Unit of Clinical Biostatistics and Aalborg AF Study Group, Aalborg, Denmark

Introduction: The plant-derived omega-3 fatty acid alpha-linolenic acid (ALA) has been associated with potential anti-atherosclerotic properties and has been suggested as a major explanation behind the beneficial effect of the Mediterranean diet in the prevention of coronary heart disease. However, limited evidence exists whether ALA is associated with a lower risk of ischemic stroke.

Purpose: The objective was to investigate the association between adipose tissue content of ALA as an objective long-term biomarker of intake of ALA and the risk of ischemic stroke.

Methods: A total of 57,053 participants aged 50–64 years of age were enrolled between 1993–97 into the Danish Diet, Cancer and Health Cohort. Potential participants were selected on the basis of BMI, waist circumference, and a random stratified sampling of the total cohort (n=3500). Statistical analyses were performed using standard statistical software, and hazard ratios with 95% confidence intervals were computed.

Conclusion: We observed a U-shaped association between adipose tissue content of ALA and the risk of ischemic stroke, but the association was not statistically significant.